Seventy-nine patients with colorctal adenomata were randomised to receve calcium carbonate (3,000 mg) or plaebo in a double-blnd randomised trial to assms the short-and long-term effects on rectal mucosal proiferation mesued by the in vitro aas arrt technique crypt cell producton rate (CCPR). There was no signifkant difference in mean CCPR between the groups before treatment or after 3 or 12 months. In those paients randonised to calcium, CCPR fel at both 3 months [9.0 (2.8) It is becoming clear that while genetic changes play an important part in the genesis of colorectal cancer the major influences are likely to be dietary (Armstrong, 1975; Fearon and Vogelstein, 1990; Willett et al., 1990) . Diet is complex in most societies, and identifying those constituents which substantially influence the risk of colorectal cancer is the subject of much study (Armstrong, 1975; Willett et al., 1990; Thun et al., 1993) . The results of such studies are not as yet clear and are often conflicting, but it would appear that a diet which is high in animal fat and low in fibre is associated with a high risk; conversely, a diet low in fat and high in fibre appears to be protective (Armstrong, 1975; Willett et al., 1990 ).
It is becoming clear that while genetic changes play an important part in the genesis of colorectal cancer the major influences are likely to be dietary (Armstrong, 1975; Fearon and Vogelstein, 1990; Willett et al., 1990) . Diet is complex in most societies, and identifying those constituents which substantially influence the risk of colorectal cancer is the subject of much study (Armstrong, 1975; Willett et al., 1990; Thun et al., 1993) . The results of such studies are not as yet clear and are often conflicting, but it would appear that a diet which is high in animal fat and low in fibre is associated with a high risk; conversely, a diet low in fat and high in fibre appears to be protective (Armstrong, 1975; Willett et al., 1990 ).
An attempt to modify diet in order to reduce cancer risk is seen as a possible goal. However, there are two major difficulties in determining efficacy in diet intervention. The first is deciding which element of the diet to modify and the second is the end point required. Clarly the best end point is the reduction in mortality from colorectal cancer. However, this would require very large numbers of individuals to be recruited and studied over decades. Intermediate end points have therefore been sought, the most obvious of which is the adenoma, widely held as the benign precursor of most cancers (Morson, 1974) . The incidence of new adenomas or the change in size of existing adenomas may be useful, since intervention may cause either a reduction in the number of new adenomas formed in a 'clean colon' or reduction in growth or regression of existing adenomas. Fmally, one can utilise changes in rectal mucosal proliferation. An increase in mucosal proliferation is thought to be an early step in the genesis of colorectal neoplasia (Fearon and Vogelstein, 1990) . We have previously shown that individuals at increased risk of colorectal cancer have elevated mucosal proliferation (Rooney et al., 1993a) , and this finding has been confirmed by others (Terpstra et al., 1987; Anti et al., 1993) . Reduction of rectal mucosal proliferation by an intervention may be evidence of an effect on reduction of risk of colorectal cancer and perhaps a modification of the progression to cancer.
A number of investigators have studied the effect of calcium on the risk of colorectal cancer. There is some epidemiological evidence that diets high in calcium may be protective for colorectal cancer (Garland et al., 1985; Sorenson et al., 1988) . There is no ckar mechanism of action, but much of its action is thought to be by binding faecal bile acids and rndeinng them insoluble in the colonic lumen (Rafter et al., 1986; Van De Meer et al., 1990) . Faecal bile acids have been shown to be tumour promoters in animals (Reddy et al., 1976) (Appleton et al., 1987) . In addition, calcium has a antiproliferative action on colonic mucosal proliferation, as increasing concentrations of calcium in organ culture systems reduces proliferation in human colonic explants (Appleton et al., 1991a) .
A number of small, clinical, non-randomised studies of calcium intervention have shown a significant fall in rectal mucosal proliferation in those taking calcium (Lipkin and Newmark, 1985; Rozen et al., 1989) . There have been some small randomised placebo-controlled trials. A study by Stern et al. (1990) was limited to 36 patients with familial polyposis coli who had previously undergone sub total colctomy and ileonetal anastomosis. These patients demonstrated a fall in mucosal proliferation 3 months after the administration of calcium, but this effect was not seen at 9 months. Wargovich et al. (1992) reported a crossover study of 20 patients with sporadic adenomas which was single blind and showed no effect of calcium at a dose of 1.2gday-' but a significant effect at 2 g day-'. A further study in adenoma patients has been reported by Bostick et al. (1993) , and again no significant effect was found.
Tbese studies have been small and lasted only a short period of time. We have undertaken a placebo-controled, randomised, double-blind study of calcium supplementation in patients with adenomas. The end points were the occurrence of new adenomas, change in size of small adenomas (<5 mm) left in situ and changes in mucosal proliferation. The study is designed to run over 2 years, but we are able to report the effects on rectal mucosal proliferation at 1 year. years, hyperparathyroidism, abnormal serum calcium or serum creatinine levels at the first visit, familial polyposis, inflammatory bowel disease or intestinal malabsorption syndromes. The patients were seen by a doctor and/or study nurse prior to recruitment to assess suitability. A total of 641 individuals were considered, and 414 were sent invitations. A total of 138 patients responded to the invitation, of whom 59 (43%) declined inclusion in the study and 79 were recruited.
The patients were seen in a special dietary intervention study clinic, the study was fully explained by a doctor (NCA and PSR) and written consent was obtained. Blood was taken to assess liver function tests, serum calcium and renal function.
These tests were repeated after 3 months. Recruited patients underwent rectal biopsy 8 cm from the anal verge at 0, 3 and 12 months using no bowel preparation or after preparation with polyethyklne glycol and electrolytes (Klean Prep, Norgine, Oxford, UK), which we and others have shown to have no effect on rectal mucosal proliferation and histological appearance (Pockros and Foroozan, 1985; Fireman et al., 1989; Rooney et al., 1993b) . A number of samples (usually four or five) were taken, with one being sent for histological confirmation of normality.
Patients were randomised to receive six tablets daily, giving a total of 1,500mg of calcium (approximately 3,000 mg of calcium carbonate) or placebo in tablet form. The tablets looked and tasted kientical. The subjects and nmeical personnel involved in the trial were unaware of the treatment each individual was taking. At each follow-up vit, questionnaires compliance and any side-effects, inluding symptoms and signs of hypercacaemia, abdominal pain and constipation, etc.
Mucosal proliferation was measured by the metaphase arrest technique and the crypt cell production rate (CCPR) alculated (Wright and Appleton, 1980, Rooney et al., 1993b) . The biopsies were dividled into 2 mm portions (explants) and placed in tissue culture mum RPMI-1640 (Gibco, Paisley, UK), to which was added 0.001 % genamicin (Nicholas Pharmaceuical, Slough, UK) and 10% fetal calf serum (Sigma, Poole, UK). The samples were stored overnight (16 h) to allow for any extraction artefact (Appleton et al., 1991b) . In order to complete the assay the explants were incubated with medium containing 1 ml of 5 sag-' ml vncristine in an atmosphere of 5% carbon dioxide and 95% oxygen. The explants were then removed at 25, 50 and 75min, fixed in Carnoy's solution for 2-4h and then stored in 70% ethanol (Rooney et al., 1993a,b year. Four patients did not complete 1 year, one died of unrelated causes (myocardial infarction), two failed to comply and the fourth developed hypercakaemic symptoms. Of the patients remaining, the compliance was > 80% based on tablet counts and interviws by the study nurse. The pretreatment CCPR for both groups is shown in Figure 1 . There was no staisticaBlly significant difference in the CCPR values between the groups. The mean CCPRs after 3 and 12 months' suppklmentation are shown in Figures  2 and 3 . No signint differences in proliferation between the calcium group and control group were observed at 3 or 12 months.
There were changes in CCPR over the time peniod. In the calcium-treated group there was a reduction in CCPR at 3 months with a reduction in mean CCPR (SD) from 12.2 (± 5.5) ccc-'h-' before treatment to 9 (± 2.8) ccc-' h-' at 3 months (t = 3.15, d.f. = 76, P = 0.002). At 12 months this reduction was maintained: mean CCPR 9.3 (± 3.3) cc c-' h-' (Lipkin and Newmark, 1985; Lipkin et al., 1989; Rozen et al., 1989) ; whethr it will reduce a 'normal' level still further is undetermined (Lipkin et al., 1989) . From our data, a reduction to 'normal' levels was seen in both groups such that there was no difference between the two groups at 3 and 12 months. In this study initial levels of rectal mucosal proliferation were similar to a previous study (Rooney et al., 1993a) Change in rectal mucosal proliferation from baseine I year in both calcium (U) and placebo (0) ed because they were over the age limit, had current medical illness, were on other medication or were difficult to colonoscope.
Of patients who were eligible, only about 60% of those who responded to the initial invitation were eventually recruited into the study. However, having started the study, the rate of retention at 12 months was 95%. The high rate of retention in the study is due to a number of factors. Firstly, the patients were counselled carefully before being recruited and were therefore well aware of the need to take their tablets consistently and that the study would run for 2 years. The second important factor was communication and reinforcement by our research nurse (KAG), who kept in close contact with the subjects over the 2 year period and delivered the medication on a 3 monthly basis, either personally or by post. In addition a direct lie to our research secretary ensured that the patients could easily contact the team for advice. In mounfing further studies consideration should be given to initial colling and continuing support for patients recruited. It is something of a burden to continue to take tablets over a prolonged period of time, and a high level of encouragement must be given for patients to remain in the study.
Only one patient dropped out at 12 months because of perceived side-ects, and it is not yet known whether she was taking calcium or placebo medication. If the calcium group only is compared at the time points, then a reduction in CCPR was observed, which may represent an effect. However, as previously mentioned, other randomised studies of calcium have shown either only transient or no effect on proliferation at this dosage (Stem et al., 1990; Wargovich et al., 1992; Bostick et al., 1993) .
The dose of calcium used was 1,500 mg daily. Initial work by Upkin and Newmark (1985) in patients with hereditary non-polyposis colorectal cancer utilised 1,250 mg of calcium which brought about a reduction in rectal mucosal proliferation as was found in other studies (Lipkin et al., 1989; Rozen et al., 1989) . However, Wargovich et al. (1992) recently showed that, in their trial of patients with sporadic adenomas, 1.2 mg of calcium carbonate was insuffiient to reduce mucosal proliferation, whereas 2.0 g did significantly reduce rectal mucosal proliferation. The dosage that we are using is similar to that used by the European Cooperative Cancer Prevention (ECP) trial, which has three arms, the others being igula husk and placebo (Faivre et al., 1991 , 1992) . Clearly this is an observation which requires further study, and as our patients come to the end of their second year in the study it should be possible to take simultaneous left colonic and rectal biopsies to determine whether there are any differences between these. In siummary, epidemiological and experimental evidence has suggested that calcium may have a role in decreasing the risk from colorectal cancer. We found a reduction in rectal mucosal proliferation compared with pretreatment levels in a group of patients with increased risk given calcium. However, there was no difference overall between calcium and placebo groups. The effect of intervention on adenomas and proliferation at the end of the study is awaited.
